Literature DB >> 20094102

[Bisphosphonate-related osteonecrosis of the jaws. An update].

F Cardona1, J V Bagán, E Sáinz, J Figuerido, F Giner, F J Vidán.   

Abstract

Bisphosphonates are widely used drugs, primarily for osteoporosis and also in oncology. A drug-induced side effect or complication, which only recently came to light in 2003, is osteonecrosis of the jaw. This study reviews the chemical characteristics of the various bisphosphonates, their possible mechanism of action, relative potency, the commercial products available on the spanish pharmaceutical market and the indications for bisphosphonate treatment. The study also considers osteonecrosis of the jaw with regard to its onset, concept, clinical stages, why this pathology affects the jaws, its risk factors, incidence, the attitude to be adopted by dentists with patients taking bisphosphonates, a quick review of the treatment and the possible prediction of osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20094102     DOI: 10.23938/ASSN.0138

Source DB:  PubMed          Journal:  An Sist Sanit Navar        ISSN: 1137-6627            Impact factor:   0.829


  4 in total

1.  [Osteonecrosis of the jaws secondary to oral bisphosphonates: a presentation of 3 cases].

Authors:  Francisco Cardona Tortajada; Esther Sainz Gómez; Fernando Giner Muñoz; Jorge Figuerido Garmendia
Journal:  Aten Primaria       Date:  2011-04-15       Impact factor: 1.137

2.  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.

Authors:  A Kyrgidis; M P Yavropoulou; R Lagoudaki; C Andreadis; K Antoniades; D Kouvelas
Journal:  Osteoporos Int       Date:  2016-11-17       Impact factor: 4.507

3.  Criteria for the prescription of oral bisphosphonates for the treatment of osteoporosis in a series of women referred for tooth extraction.

Authors:  Márcio Diniz-Freitas; Javier Fernández-Feijoo; Paula Fernández-Montenegro; Antonio González-Mosquera; Emma Vázquez-García; Pedro Diz-Dios
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-07-01

4.  [Oral bisphosphonates, denosumab and osteonecrosis of the jaws].

Authors:  Francisco Cardona Tortajada; Esther Sainz Gómez; David Viñal Lozano
Journal:  Aten Primaria       Date:  2014-12-15       Impact factor: 1.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.